Everything you need to know
about biosimilars in one place

Novartis Launches First U.S. ‘Biosimilar’ Drug at 15% Discount

Novartis Launches First U.S. ‘Biosimilar’ Drug at 15% Discount   Novartis’ Zarxio is the biosimilar of Amgen’s biologic, Neuopgen. It is expected the due to the fact that Zarxio will be sold at cheaper price, it will increase access to treatment.  Amgen had tried to stop Zarxio from reaching the market many times, but with no avail.  … Continue reading Novartis Launches First U.S. ‘Biosimilar’ Drug at 15% Discount

Read more

U.K. Health Body Recommends Remicade Biosimilars Over Patented Reference Drug

Public health body NICE has favored two Remicade biosimilars ahead of the reference drug in draft guidance. The United Kingdom’s National Institute for Health and Care Excellence (NICE) has reportedly recommended two biosimilar versions of infliximab over Remicade, the top-selling original medicine patented by Janssen/MSD (Merck) – which makes more than $8 billion a year … Continue reading U.K. Health Body Recommends Remicade Biosimilars Over Patented Reference Drug

Read more

ASBM Slams Australia for Backing Unsupervised Biosimilar Substitution

The Alliance for Safe Biologic Medicines calls the decision a “retrograde step” amid widespread global opposition to automatic biosimilar substitution by pharmacists.   The Alliance for Safe Biologic Medicines (ASBM) has released a press release, condemning recent announcements by Australian Health Minister Sussan Ley and the Pharmaceutical Benefits Advisory Committee (PBAC) that Australia would “break … Continue reading ASBM Slams Australia for Backing Unsupervised Biosimilar Substitution

Read more

EULAR Position Paper Reveals Patients Wary of Biosimilars

A paper presented at EULAR says patients don’t yet trust – or fully understand – biosimilars, and want access to clinical data.   A position paper published by the European League Against Rheumatism (EULAR) reveals that patients don’t understand the science behind biosimilars and are nervous about being treated with them. In fact, “the implications … Continue reading EULAR Position Paper Reveals Patients Wary of Biosimilars

Read more

Finnish Study Finds Patients Safely Switch from Remicade to Biosimilar

A recent Finnish study has demonstrated that patients with rheumatic diseases can be safely and effectively switched from original-brand medicine to a biosimilar version.   A Reuters article reports that the results of the independent study were presented at the recent European League Against Rheumatism Congress in Rome, by one of its researchers, Tuulikki Sokka … Continue reading Finnish Study Finds Patients Safely Switch from Remicade to Biosimilar

Read more

South Korea Comes to the Fore in Biosimilars Space

Aided by government funding and big pharma partnerships, South Korea is staking its claim on biosimilars, with Celltrion and Samsung the main contenders.   South Korea is pushing to be a leader in the biopharmaceuticals field, so says a recent Financial Times report. While that country’s Celltrion is already a big player in manufacturing, partnering … Continue reading South Korea Comes to the Fore in Biosimilars Space

Read more

Merck, Biogen, Samsung Partnerships Present Promising Data at EULAR Congress

At the recent EULAR Congress, the joint ventures between Merck, Biogen and Samsung bore fruit with promising biosimilars data presented.   As emerging and established biopharmaceuticals companies scramble for a place in the biosimilars space, clinical trial data presented at the recent European League Against Rheumatism (EULAR) Annual Congress in Rome shows promise for more … Continue reading Merck, Biogen, Samsung Partnerships Present Promising Data at EULAR Congress

Read more

ANVISA Approves First Infliximab Biosimilar in Brazil

The National Health Surveillance Agency (ANVISA) in Brazil has approved the use of the monoclonal antibody Remsima (infliximab) from Hospira Inc. and its partner Celltrion.   Remsima is responsible for the treatment of, “rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn’s disease in adults and children, fistulizing Crohn’s disease (advanced), colitis and ulcerative rectocolitis.” This … Continue reading ANVISA Approves First Infliximab Biosimilar in Brazil

Read more